MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds, net of 8,750 and
7,238 expenses, from...
$237,940K
Net cash provided by
financing activities
$214,530K
Canceled cashflow
$23,410K
Net increase in
cash, cash...
$110,127K
Canceled cashflow
$104,403K
Repurchase of common stock,
net of 30 expenses
$13,760K
Repayments of term loan
$9,650K
Accrued expenses and
other current...
$11,745K
Stock-based compensation
$6,017K
Accounts payable
$2,994K
Loss on
extinguishment of debt
-$2,092K
Depreciation and
amortization
$1,925K
Issuance costs of
derivative instrument
$1,837K
Inventory
-$1,726K
Loss on note
-$1,159K
Inventory write-off
$669K
Amortization of debt
discounts
$65K
Bad debt expense
$31K
Proceeds from note
$853K
Net cash used in
operating activities
-$99,844K
Net cash used in
investing activities
-$4,528K
Effect of currency rate
change on cash
-$31K
Canceled cashflow
$30,260K
Canceled cashflow
$853K
Net loss
-$124,021K
Purchase of property and
equipment
$3,369K
Issuance of note
$2,012K
Prepaid expenses and
other
$3,161K
Accounts receivable
$2,619K
Operating lease
liabilities and rou asset,...
-$303K
Back
Back
Cash Flow
source: myfinsight.com
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)